Novartis Oncology plans acceleration of Russian expansion

Swiss pharma giant Novartis (NOVN: VX) is considering accelerating expansion in the Russian market of anti-cancer drugs in the coming years, according to the company.

Bruno Strigini, chief executive of Novartis Oncology said that, in recent years the cancer rate in Russia has significantly increased, which has resulted in increased demand for high-quality, innovative drugs for the treatment of the disease, reports The Pharma Letter’s Russian correspondent.

In this regard, the company considers more active expansion in the Russian pharmaceutical market, however much will depend on its scheme of cooperation with the state and the ability to protect the invested funds.